COVID-19 rapid guideline : managing the long-term effects of COVID-19 (Record no. 3788)

MARC details
000 -LEADER
fixed length control field 01972nam a22002297a 4500
001 - CONTROL NUMBER
control field D0001C000163
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20210326111328.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 210326b ||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Description conventions rda
245 00 - TITLE STATEMENT
Title COVID-19 rapid guideline : managing the long-term effects of COVID-19
Remainder of title managing the long-term effects of COVID-19
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. London :
Name of publisher, distributor, etc. National Institute for Health and Care Excellence,
Date of publication, distribution, etc. 2020.
336 ## - CONTENT TYPE
Source rdacontent
Content type text
337 ## - MEDIA TYPE
Source rdamedia
Media type unmediated
338 ## - CARRIER TYPE
Source rdacarier
Carrier type term volume
520 ## - SUMMARY, ETC.
Summary, etc. This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.<br/><br/>This guideline has been developed jointly by NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners (RCGP).<br/><br/>To develop the recommendations, we have used the following clinical definitions for the initial illness and long COVID at different times:<br/><br/>Acute COVID-19: signs and symptoms of COVID-19 for up to 4 weeks.<br/><br/>Ongoing symptomatic COVID-19: signs and symptoms of COVID-19 from 4 to 12 weeks.<br/><br/>Post-COVID-19 syndrome: signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis.<br/><br/>When using this guideline, follow the usual professional guidelines, standards and laws (including those on equalities, safeguarding, communication and mental capacity), as described in making decisions using NICE guidelines.
600 #2 - SUBJECT ADDED ENTRY--PERSONAL NAME
Field link and sequence number COVID-19
600 #2 - SUBJECT ADDED ENTRY--PERSONAL NAME
Field link and sequence number Long Term Adverse Effects
600 #2 - SUBJECT ADDED ENTRY--PERSONAL NAME
Field link and sequence number Guideline
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.ncbi.nlm.nih.gov/books/NBK567261/">https://www.ncbi.nlm.nih.gov/books/NBK567261/</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme National Library of Medicine
Koha item type COVID 19 Resource
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
    National Library of Medicine     DOH Central Library DOH Central Library Electronic Resource Section 03/26/2021   COVID-19-000163 D0001C000163 03/26/2021 03/26/2021 COVID 19 Resource